J&J Sees Growth Opportunities Through Partnerships And Emerging Markets After Facing Early Patent Cliff
Executive Summary
Johnson & Johnson is increasingly looking to partnerships as part of its strategy to bounce back from the onset of generic competition for its mega drugs Risperdal Oral (risperidone) and Topamax (topiramate)
You may also be interested in...
J&J Strengthens Diabetes Pipeline With Two Deals
A late-stage deal for a type 1 treatment and an early-stage deal for a series of type 2 compounds help J&J's move into diabetes, where it has traditionally been strong in blood glucose monitoring.
J&J Strengthens Diabetes Pipeline With Two Deals
A late-stage deal for a type 1 treatment and an early-stage deal for a series of type 2 compounds help J&J's move into diabetes, where it has traditionally been strong in blood glucose monitoring.
Device Firms Stand To Lose Market Opportunities If Health Care Reform Dies
With the fate of comprehensive health care reform in serious doubt at the eleventh hour, many in the device industry may be breathing a sigh of relief that the device tax could be avoided or at least lessened. But if the reform bill dies, the industry will also lose out on the potential 30 million additional health care customers slated to gain insurance under its provisions